Biotechnology News and Research

RSS

Nuvilex describes advantages of cell encapsulation technology for multiple cancer therapies

Nuvilex, Inc. described today potential advantages of cell encapsulation technology for use in cancer therapies when more than one cancer-fighting drug is used.

17 Jun 2011

Experimental vaccine shows promise for patients with newly diagnosed brain tumors

An experimental vaccine developed by researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute targets overactive antigens in highly aggressive brain tumors and improves length of survival in newly diagnosed patients, according to new data that was presented in a poster session at the 47th Annual Meeting of the American Society of Clinical Oncology.

17 Jun 2011

BGI releases first complete map of Germany E. coli O104:H4 genome

Building upon previous efforts producing a high-quality de novo genome assemblies of deadly 2011 E. coli O104:H4 outbreak strain, the BGI and their collaborators at the University Medical Centre Hamburg-Eppendorf have now released the first complete map of the genome and plasmids without any assembly gaps.

17 Jun 2011

Elsevier announces two new biomedical applications from Molecular Connections

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced two new applications from Molecular Connections, a life science informatics company, on SciVerse Applications beta.

17 Jun 2011

Transgenomic introduces Nuclear Mitome Test for diagnosis of mitochondrial disorders

Transgenomic, Inc. today announced the launch of the Nuclear Mitome Test, a genetic test to aid physicians in the diagnosis of mitochondrial disorders.

17 Jun 2011

Theorem Clinical Research receives contract to conduct Nordion's TheraSphere Phase III trials

Nordion Inc., a leading provider of products and services to the global health science market, today announced that Theorem Clinical Research, previously Omnicare Clinical Research, a full service Contract Research Organization has been awarded the contract to conduct Nordion's recently announced TheraSphere Phase III clinical trials for the treatment of primary and metastatic liver cancers - STOP-HCC and EPOCH.

16 Jun 2011

ADDF, AFTD invite scientists to apply for Frontotemporal Dementia-specific biomarker grants

The Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Degeneration invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia (FTD)-specific biomarkers that reflect pathological and clinical differences so that appropriate patients can be selected for clinical trials and responses to investigational treatments can be monitored.

16 Jun 2011

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin and dacetuzumab programs will be presented at the 11th International Conference on Malignant Lymphoma being held June 15-18, 2011 in Lugano, Switzerland.

16 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Neogenix Oncology, Inc. is pleased to announce it has signed an agreement with Cambridge Biomedical, Inc, based in Boston, MA, for the development of its pancreatic and colorectal cancer diagnostic serum ELISA assays.

16 Jun 2011

ISSCR honors UCSF cancer scientist with 2011 Outstanding Young Investigator Award

UCSF's Robert Blelloch, MD, PhD, has received the 2011 Outstanding Young Investigator Award from the International Society for Stem Cell Research, for his pioneering research on the role of molecular tools known as microRNAs in embryonic stem cells and cancer.

16 Jun 2011

Life Technologies introduces CytoTune-iPS Reprogramming Kit

Life Technologies Corporation today announced the launch of CytoTune-iPS Reprogramming Kit -- research technology that provides far improved efficiency over standard methods to develop induced pluripotent stem cells from human somatic cells.

16 Jun 2011

ProImmune introduces new uniquely powerful protein and peptide array platform

ProImmune Ltd., a leader in services for understanding immune responses, announced today that it has launched ProArray Ultra, a uniquely powerful protein and peptide array platform, which is more sensitive than optimized ECL ELISA.

16 Jun 2011

Placental growth factor also plays a role in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML.

15 Jun 2011

Spectrum board authorizes $25 million stock repurchase program

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that its Board of Directors has authorized the purchase of up to $25 million of its common stock through the end of 2012.

15 Jun 2011

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.

15 Jun 2011

Intralytix obtains FDA, FSIS regulatory clearance for bacteriophage-based product against E. coli

Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

15 Jun 2011

Nuvilex to acquire live cell encapsulation technology for multiple cancer therapies

Nuvilex, Inc. announced today it has entered into discussions to acquire the next generation live cell encapsulation technology that serves as the platform for multiple cancer therapies.

15 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

A type of virus known as the human reovirus possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation, while leaving the body's normal cells alone.

15 Jun 2011

Biotechnology News and Research

Nuvilex describes advantages of cell encapsulation technology for multiple cancer therapies

Experimental vaccine shows promise for patients with newly diagnosed brain tumors

BGI releases first complete map of Germany E. coli O104:H4 genome

Elsevier announces two new biomedical applications from Molecular Connections

Transgenomic introduces Nuclear Mitome Test for diagnosis of mitochondrial disorders

Theorem Clinical Research receives contract to conduct Nordion's TheraSphere Phase III trials

ADDF, AFTD invite scientists to apply for Frontotemporal Dementia-specific biomarker grants

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

ISSCR honors UCSF cancer scientist with 2011 Outstanding Young Investigator Award

Life Technologies introduces CytoTune-iPS Reprogramming Kit

ProImmune introduces new uniquely powerful protein and peptide array platform

Placental growth factor also plays a role in chronic myeloid leukemia

Spectrum board authorizes $25 million stock repurchase program

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Intralytix obtains FDA, FSIS regulatory clearance for bacteriophage-based product against E. coli

Nuvilex to acquire live cell encapsulation technology for multiple cancer therapies

QIAGEN to acquire Ipsogen

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News